

**Prof. François Mach**

**List of publications (last five years)**

**Original research articles**

40. Groscurin O, Plojoux J, Keller PF, Niquille M, N'koulou R, Mach F, Sarasin FP, Rutschmann OT. Prehospital emergency physician activation of interventional cardiology team reduces door-to-balloon time in ST-elevation myocardial infarction. **Swiss Med Wkly**. in Press 2010.
39. Montet-Abou K, Daire JL, Hyacinthe JN, Jorge-Costa M, Grosdemange K, Mach E, Petri-Fink A, Hofmann H, Morel DR, Vallée JP, Montet X. In vivo labeling of resting monocytes in the reticuloendothelial system with fluorescent iron oxide nanoparticles prior to injury reveals that they are mobilized to infarcted myocardium. **Eur Heart J**. In press, 2010.
38. Braunersreuther V, Pellieux C, Pelli G, Burger F, Steffens S, Montessuit C, Weber C, Proudfoot A, Mach E, Arnaud C. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. **J Mol Cell Cardiol**. In press, 2010.
37. Lorgelly PK, Briggs AH, Wedel H, Dunselman P, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J, Jánosi A, van Veldhuisen DJ, Barrios V, Fonseca C, McMurray JJ; CORONA Study Group. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA Trial. **Eur J Heart Fail**. 12: 66-74, 2010.
36. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Rationale and Design of the dual-OUTCOMES trial: efficacy and safety of dolcetrabip in patients with recent acute coronary syndromes. **Am Heart J**. 158: 896-901.e3, 2009.
35. Bonvini RF, Rastan A, Sixt S, Noory E, Beschoner U, Leppanen O, Mach E, Schwarzwälder U, Bürgelin K, Zeller T. Percutaneous retrieval of intravascular and intracardiac foreign bodies with a dedicated three-dimensional snare: A 3-year single center experience. **Catheter Cardiovasc Interv**. 74: 939-45, 2009.
34. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamensky G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J; for the CORONA Study Group. Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective Analysis. **Circulation**. 120: 2188-96, 2009.
33. Montecucco F, Bertolotto M, Ottonello L, Pende A, Dapino P, Quercioli A, Mach F, Dallegri F. Chlorhexidine prevents hypochlorous acid-induced inactivation of alpha-1-antitrypsin (alpha-1-AT). **Clin Exp Pharmacol Physiol**. 36: e72-e77, 2009.
32. Montecucco F, Bertolotto M, Ottonello L, Quercioli A, Mach F, Dallegri F. Oxaprozol-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways. **J Biomed Biotechnol**. 2009:478785, 2009.
31. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators. Early versus delayed, provisional eptifibatid in acute coronary syndromes. **N Engl J Med**. 360: 2176-90, 2009.

30. Vincenti G, Nkoulou R, Steiner C, Imperiano H, Ambrosio G, Mach F, Ratib O, Vallee JP, Schindler TH. Noninvasive stress testing of myocardial perfusion defects: head-to-head comparison of thallium-201 SPECT to MRI perfusion. **J Nucl Cardiol.** 16: 549-61, 2009.
29. Montecucco F, Matias I, Lenglet S, Petrosino S, Burger F, Pelli G, Braunersreuther V, Mach F, Steffens S, Di Marzo V. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. **Atherosclerosis.** 205: 433-41, 2009.
28. Pellegrin M, Alonso F, Aubert JF, Bouzourene K, Braunersreuther V, Mach F, Haefliger JA, Hayoz D, Berthelot A, Nussberger J, Laurant P, Mazzolai L. Swimming prevents vulnerable atherosclerotic plaque development in hypertensive 2-kidney, 1-clip mice by modulating angiotensin II type 1 receptor expression independently from hemodynamic changes. **Hypertension.** 53: 782-9, 2009.
27. Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, Mach E, Steffens S. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. **J Mol Cell Cardiol.** 46: 612-20, 2009.
26. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F; Ubolyam S; Carr A, Ruxungtham K, Hirschel B, Ananworanich J. HIV increases cardiovascular risk markers in a randomized, treatment interruption trial (STACCATO). **AIDS.** 23: 929-39, 2009.
25. Montecucco F, Burger F, Pelli G, Kwabena Poku N, Berlier C, Steffens S, Mach E. Statins inhibit CRP-induced chemokine secretion, ICAM-1 expression and chemotaxis in adherent human monocytes. **Rheumatology.** 48: 233-42, 2009
24. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM; IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. **Am Heart J.** 156: 826-32, 2008.
23. Saudan P, Muller H, Feraille E, Martin PY, Mach E. Renin-angiotensin system blockade and contrast-induced renal toxicity. **J Nephrol.** 21:681-85, 2008.
22. Montecucco F, Steffens S, Burger F, Pelli G, Monaco C, Mach F. C-reactive protein (CRP) induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes. **J Leukoc Biol.** 84:1109-19, 2008.
21. Fokstuen S, Lyle R, Munoz A, Gehrig C, Lerch R, Perrot A, Osterziel KJ, Geier C, Beghetti M, Mach F, Sztajzel J, Sigwart U, Antonarakis SE, Blouin JL. A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. **Hum Mutat.** 29:879-85, 2008.
20. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A, Mach F. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. **Arterioscler Thromb Vasc Biol.** 28:1090-96, 2008.
19. Montecucco F, Burger F, Mach F, Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. **Am J Physiol Heart Circ Physiol.** 294:H1145-1155, 2008.
18. Montecucco F, Steffens S, Burger F, Da Costa A, Bianchi G, Bertolotto M, Mach F, Dallegri F, Ottonello L. Tumor necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3

- (MIP-1 $\alpha$ ) on human neutrophils through defined signalling pathways. **Cell Signal.** 20:557-68, 2008.
17. von Lukowicz T, Hassa PO, Lohmann C, Borén J, Braunersreuther V, Mach F, Odermatt B, Gersbach M, Camici GG, Stähli BE, Tanner FC, Hottiger MO, Lüscher TF, Matter CM. PARP1 is required for adhesion molecule expression in atherogenesis. **Cardiovasc Res.** 78:158-66, 2008.
  16. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19\*2 allele on clopidogrel responsiveness. **Thromb Res.** 121:463-68, 2008.
  15. Vuilleumier N, Charbonney E, Fontao L, Alvarez M, Turck N, Sanchez JC, Burkhard PR, Mensi N, Righini M, Reber G, James RW, Mach F, Chevrolet JC, Dayer JM, Frostegard J, Roux-Lombard P. Anti-apolipoprotein A-1 IgG are associated with high oxidized low-density lipoprotein levels in acute coronary syndrome. **Clin Sci (Lond).** 115:25-33, 2008.
  14. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarsen A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. **N Engl J Med.** 357:2248-61, 2007.
  13. Schindler TH, Zhang XL, Vincenti G, Mhiri L, Nkoulou R, Just H, Ratib O, Mach F, Dahlbom M, Schelbert HR. Diagnostic value of PET-measured heterogeneity in myocardial blood flows during cold pressor testing for the identification of coronary vasomotor dysfunction. **J Nucl Cardiol.** 14:688-97, 2007.
  12. Packard RR, Schlegel S, Senouf D, Burger F, Sigaud P, Perneger T, Siegrist CA, Mach F. Atorvastatin treatment and vaccination efficacy. **J Clin Pharmacol.** 47:1022-1027, 2007.
  11. Dunoyer-Geindre S, Kwak BR, Pelli G, Roth I, Satta N, Fish RJ, Reber G, Mach F, Kruihof EK, de Moerloose P. Immunization of LDL receptor-deficient mice with beta2-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques. **Thromb. Haemost.** 97:129-38, 2007.
  10. Braunersreuther V, Zerneck A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E, Bidzhekov K, Burger F, Pelli G, Luckow B, Weber C, Mach F. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. **Arterioscler Thromb Vasc Biol.** 27:373-379, 2007.
  9. Steffens S, Burger F, Pelli G, Dean Y, Elson G, Kosco-Vilbois M, Chatenoud L, Mach F. Short-term treatment with CD3 antibody reduces the development and progression of atherosclerosis in mice through the induction of FoxP3-expressing regulatory T cells. **Circulation.** 114:1977-84, 2006.
  8. Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S, Mach F. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. **Atherosclerosis.** 188:51-58, 2006.
  7. Frossard J-L, Kwak B, Chanson M, Morel P, Hadengue A, Mach F. CD40 Ligand-deficient mice in pancreatitis. **World J. Gastroenterol.** 12:1613-1616, 2006.
  6. Mach F, Senouf D, Fontana P, Boehlen F, Reber G, Daali Y, de Moerloose P, Sigwart U. Not all statins interfere with clopidogrel during antiplatelet therapy. **Eur. J. Clin. Invest.** 35:476-481, 2005.

5. Veillard NR, Steffens S, Pelli G, Kwak BR, Gerard C, Lu B, Charo IF, Mach F. Differential influence of the chemokine receptors CCR2 and CXCR3 in the development of atherosclerosis in vivo. **Circulation**. 112:870-878, 2005.
4. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, James RW, Mach F, Gabay C. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. **Cardiovasc. Res**. 66:583-593, 2005.
3. Christen T, Mach F, Didier D, Kalangos A, Verin V, Trindade PT. Late cardiac tamponade after percutaneous closure of a patent foramen ovale. **Eur. J. Echocardiogr**. 6:465-469, 2005.
2. Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D, Mach F. Statins reduce interleukin-6-induced C-Reactive Protein in human hepatocytes. New evidence for direct anti-inflammatory effects of statins. **Arterioscler. Thromb. Vasc. Biol**. 25:1231-1236, 2005.
1. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer H, Frossard JL, Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. **Nature**. 434:782-786, 2005.

## Reviews

51. Quercioli A, Mach F, Montecucco F. Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). **Sleep Breath**. In press 2010.
50. Quercioli A, Mach F, Montecucco F. Novel treatment strategy with direct renin inhibition against heart failure. **Panminerva Med**. In press 2010.
49. Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the pathophysiology of essential hypertension. **J Nephrol**. In press, 2010.
48. Montecucco F, Quercioli A, Mach F. Ezetimibe/simvastatin. **Expert Opin Drug Saf**. 8: 715-25, 2009.
47. Quercioli A, Montecucco F, Mach F. Update on the Treatments of Non-Alcoholic Fatty Liver Disease (NAFLD). **Cardiovasc Hematol Disord Drug Targets**. 9: 261-70, 2009.
46. Meyer P, Kayser B, Mach F. Stair use for cardiovascular disease prevention. **Eur J Cardiovasc Prev Rehabil**. 16 Suppl 1: S17-8, 2009.
45. Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischemia and reperfusion injury. **Thromb Haemost**, 102: 240-7, 2009.
44. Yerly P, Mach F, Kalangos A, Rotman S, von Segesser L, Vogt P, Hullin R, Pascual M. Monitoring and adjustment of immunosuppression after the heart transplantation. **Rev Med Suisse**. 5: 1214-6, 1218-20, 2009.
43. Luya Schmidt A, Mach F. Takotsubo syndrome: myth or reality? **Rev Med Suisse**. 5: 1184, 1186-8, 1190-2 passim, 2009.
42. Roffi M, Pereira V, San MD, Bonvini RF, Keller PF, Mach F, Lovblad KO. Carotid stenting: an alternative to surgery? **Rev Med Suisse**. 2009 5: 1177-80, 1182-3, 2009.
41. Vogt P, Mach F. Cardiology-trends. **Rev Med Suisse**. 5: 1163-4, 2009.

40. Mach F. Ivabradine, an I(f) current inhibitor--new treatment options in coronary heart disease. **Rev Med Suisse.** 5: 1168-70, 1172-3, 2009.
39. Montecucco F, Mach F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. **Semin Immunopathol.** 31: 127-142, 2009.
38. Montecucco F, Mach F. ACE-inhibitors and ARB in cardiovascular disease. **Best Pract Res Clin Endocrinol Metab.** 23: 389-400, 2009.
37. Montecucco F, Mach F. Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome. **Diabetes, Obesity and Metabolism.** 11: 445-454, 2009.
36. Bonvini RF, Reny JL, Mach F, Zeller T, Fontana P. Acute coronary syndrome and its antithrombotic treatment: focus on aspirin and clopidogrel resistanc. **Curr Vasc Pharmacol.** 7: 198-208, 2009.
35. Lévy P, Pépin JL, Arnaud C, Baguet JP, Dematteis M, Mach F. Obstructive sleep apnea and atherosclerosis. **Prog Cardiovasc Dis.** 51: 400-10, 2009.
34. Montecucco F, Mach F. Therapeutic approaches for reducing C-reactive protein (CRP) levels and the associated cardiovascular risk. **Current Chemical Biology.** 3: 60-64, 2009.
33. Montecucco F, Pende A Mach F. The renin-angiotenin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical trials. **Mediators Inflamm.** 2009:752406, 2009.
32. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. **Rheumatology.** 48:11-22, 2009.
31. Mach F, Montecucco F, Steffens S. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk. **Pharmacol Rep.** 61:13-21, 2009.
30. Montecucco F, Mach F. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk? **Endocrine, Metabolis & Immune Disorders – Drug Targets.** 8: 301-307, 2008.
29. Montecucco F, Mach F. Traitement du diabète de type 2: Blocage du système endocannabinoïde avec le rimonabant. **Cardiovasc.** 7:18-20, 2008.
28. Montecucco F, Mach F. New evidences for C-reactive protein (CRP) deposits in arterial intima as a cardiovascular risk factor. **Clin. Interv. Aging.** 3:341-349, 2008.
27. Montecucco F, Steffens S, Mach F. Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. **Mediators Inflamm.** 767623, 2008.
26. Mach F, Vogt P. The importance of patient education in cardiology. **Rev. Med. Suisse.** 4:1299-300, 2008.
25. Sekoranja L, Bianchi-Demicheli F, Gaspoz JM, Mach F. Heart failure and sexual dysfunction. **Rev. Med. Suisse.** 4:763-67, 2008.
24. Mach F, Steffens S. The role of the endocannabinoid system in atherosclerosis. **J. Neuroendocrinol.** 20 Suppl 1:53-57, 2008.
23. Mach F, Montecucco F, Steffens S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. **Br. J. Pharmacol.** 153:290-98, 2008.

22. Montecucco F, Steffens S, Mach F. Inflammation as coronary risk factor. **ARS MEDICI.** 23:1145-1152, 2007.
21. Montecucco F, Steffens S, Mach F. The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? **Clin. Dev. Immunol.** 75805, 2007.
20. Mach F. The endocannabinoid system as therapeutic target to reduce atherosclerosis. **Drug News Perspect.** 2007.
19. Clark R, Mach F. L'Ezitimibe sous la loupe. **Drug in Context.** 2007.
18. Braunersreuther V, Mach F., Steffens S. The specific role of chemokines in atherosclerosis. **Thromb Haemost.** 97:714-21, 2007.
17. Purcell H, Mach F. Heart rate as a cardiovascular risk factor: potential clinical benefit with ivabradine. **Rev. Med. Suisse.** 3:1375-8, 2007.
16. Steffens S, Mach F. Cannabinoid receptors in atherosclerosis. **Curr. Opin. Lipid.** 17:519-26, 2006.
15. Braunersreuther V, Mach F. Leukocytes recruitment in atherosclerosis: Potential targets for therapeutical approaches ? **Cell. Mol. Life. Sci.** 63:2079-88, 2006.
14. Steffens S, Mach F. Immunomodulatory effects of statins: Potential benefits for renal patients. **Nat. Clin. Pract. Neph.** 2:378-87, 2006.
13. Mach F. New anti-inflammatory agents to reduce atherosclerosis. **Arch. Physiol. Biochem.** 112:130-7, 2006.
12. Arnaud C, Mach F. Potential anti-inflammatory and immunomodulatory effects of statins in rheumatologic therapy. **Arthritis Rheum.** 54:579-586, 2006.
11. Mach F. New anti-inflammatory agents to reduce atherosclerosis. **NAF Review** 3:2, 2006.
10. Sekoranja L, Bianchi-Demicheli F, Gaspoz JM, Mach F. Erectile dysfunction: a potential useful marker for cardiovascular disease. **Rev. Med. Suisse** 2:774-778, 2006.
9. Steffens S, Mach F. Vers un usage thérapeutique de ligands sélectifs du récepteur cannabinoïde 2 dans l'athérosclérose. **Med. Sci.** 22:7-9, 2005.
8. Steffens S, Mach F. Towards a therapeutic use of selective CB2 cannabinoid receptor ligands for atherosclerosis. **Future Cardiol.** 2:49-53, 2005.
7. Mach F. Inflammation is a crucial feature of atherosclerosis and a potential target to reduce cardiovascular events. **Handb. Exp. Pharmacol.** 170:697-722, 2005.
6. Mach F. Traitement antithrombotique et thrombolytique: Commentaire des experts suisses concernant les EBM-guideles internationales. **Swiss Med. Wkly.** 28:28S-33S, 2005.
5. Arnaud C, Braunersreuther, Mach F. Towards immunodulatory and anti-inflammatory properties of Statins. **Trends Cardiovasc. Med.** 15:202-206, 2005.
4. Arnaud C, Mach F. Pleiotropic effects of statins in atherosclerosis. **Arch. Mal. Coeur Vaiss.** 98:661-666, 2005.

3. Arnaud C, Veillard N, Mach F. Cholesterol-independent effects of statins. **Curr. Drug. Targets.** 5:127-134, 2005.
2. Fokstuen S, Blouin JL, Lyle R, Lerch R, Beghetti M, Mach F, Sztajzel J, Antonarakis SE, Sigwart U. The contribution of molecular genetics to clinical cardiology: the example of hypertrophic cardiomyopathy. **Rev. Med. Suisse.** 1:1448-1450, 2005.
1. Braunersreuther V, Mach F. Mécanisme d'action des statines: A la recherche des effets pléiotropiques ? **Cardiovasc.** 3:24-27, 2005.

### Editorials

2. Montecucco F, Mach F. Atherosclerosis is an inflammatory disease. **Semin Immunopathol.** 31: 1-3, 2009.
1. Steffens S, Mach F. Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis. **Circ. Res.** 102: 140, 2008.

### Letters

1. Kwak BR, Mach F. Reply to "Statins and the control of CIITA transcription". **Nat. Med.** 11: 366-367, 2005.

### Book chapters

5. Montecucco F, Quercioli A, Mach F. Role of Neutrophils in acute myocardial infarction. Handbook entitled "Neutrophils: Lifespan, Functions and role in Disease", **Nova Science Publishers**, in press 2010.
4. Vuille C, Mach F. Prévention Cardiovasculaire: Moyens Thérapeutiques. **Edition Médecine & Hygiène**, 2009.
3. Mach F. Statins in atherosclerosis: Role of immune regulation. Immune Dysfunction and Immunotherapy in Heart Disease. **Ronald R. Watson & Douglas F. Larson Editors. Blackwell**, 2006.
2. Mach F. Statines et médicaments hypolipémiants. **Edition Médecine & Hygiène**, 2006.
1. Mach F. Inflammation is a crucial feature of atherosclerosis and a potential target to reduce cardiovascular disease. Atherosclerosis: Diet and Dugs. **Arnold von Eckardstein Editor. Springer**, 2005.